KFAS
STLN

Keating Financial Advisory Services’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Keating Financial Advisory Services’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Buy
+1
New +$3 ﹤0.01% 2557

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Keating Financial Advisory Services's STLN Position: Q1 2026 in Review

Keating Financial Advisory Services opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 1 share worth $3. The stake represents ﹤0.01% of the portfolio and ranks #2557 among its holdings.

115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Keating Financial Advisory Services held 1 share of Starling Oncology Institute, Inc. Common Stock worth $3 as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Keating Financial Advisory Services position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2557 holding.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.